By: Jordana Joy, Associate Editor
The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.
The first patient has been dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111 in patients with normal-tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s lead investigational therapy, will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with NTG and will be conducted at multiple clinical sites across South Korea, according to a news release.
“NTG is highly prevalent in Asia and many of our patients struggle with ongoing vision loss despite intraocular pressures (IOP) that appear ‘normal’ by conventional standards,” said Ki Ho Park, MD, PhD, professor of ophthalmology at Seoul National University College of Medicine and lead investigator of the Nightingale study, in the release. “We are excited to evaluate QLS-111. A therapy that targets episcleral venous pressure (EVP) may offer a much-needed new strategy for pressure reduction and disease control in this population.”
QLS-111 is a first-in-class ATP-sensitive potassium channel modulator designed to lower IOP by reducing EVP. Qlaris Bio noted that this therapy is particularly relevant for patients with NTG whose IOPs remain within a healthy range but continue to experience disease progression.1
Read more: https://tinyurl.com/e8t7yhyd
Source: Optometry Times